Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetrelimab - Janssen Research and Development

Next Previous
Drug Profile

Cetrelimab - Janssen Research and Development

Alternative Names: JNJ 63723283; JNJ-3283; WHO-10757

Latest Information Update: 28 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ankyra Therapeutics; Janssen Research & Development
  • Developer Janssen Research & Development
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase II/III Multiple myeloma
  • Phase II Prostate cancer
  • Phase I/II Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • No development reported Hepatitis B

Most Recent Events

  • 28 Jun 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)
  • 28 Jun 2026 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Japan (IV, Infusion)
  • 31 Mar 2026 Janssen Research & Development completes a phase II SunRISe-4 trial in Bladder cancer (Neoadjuvant therapy, Combination therapy, Monotherapy) in Belgium, France, Germany, Israel, Italy, Netherlands, South Korea, Spain, United Kingdom and USA (IV) (NCT04919512)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top